ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update

ALX Oncology Holdings Inc. (NASDAQ:ALXO) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 3,120,000 shares, a growth of 7.2% from the March 15th total of 2,910,000 shares. Based on an average daily volume of 389,200 shares, the short-interest ratio is currently 8.0 days. Approximately 11.5% of the company’s shares are short sold.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Friday, April 12th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of ALX Oncology in a report on Wednesday, April 10th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $14.00 price target (up from $10.00) on shares of ALX Oncology in a report on Friday, March 8th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, ALX Oncology currently has an average rating of “Moderate Buy” and a consensus price target of $18.83.

Insider Activity

In other news, insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $11.15, for a total value of $223,000.00. Following the completion of the sale, the insider now directly owns 628,359 shares of the company’s stock, valued at approximately $7,006,202.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Jason Lettmann acquired 4,400 shares of the stock in a transaction dated Thursday, March 14th. The stock was acquired at an average cost of $11.31 per share, with a total value of $49,764.00. Following the purchase, the chief executive officer now directly owns 171,620 shares of the company’s stock, valued at $1,941,022.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $11.15, for a total value of $223,000.00. Following the completion of the sale, the insider now directly owns 628,359 shares of the company’s stock, valued at $7,006,202.85. The disclosure for this sale can be found here. Corporate insiders own 50.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ALXO. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in ALX Oncology during the 4th quarter worth $28,000. Royal Bank of Canada increased its holdings in shares of ALX Oncology by 226.6% in the 2nd quarter. Royal Bank of Canada now owns 4,001 shares of the company’s stock valued at $30,000 after acquiring an additional 2,776 shares during the period. Legal & General Group Plc increased its holdings in shares of ALX Oncology by 42.6% in the 4th quarter. Legal & General Group Plc now owns 2,289 shares of the company’s stock valued at $34,000 after acquiring an additional 684 shares during the period. UBS Group AG increased its holdings in shares of ALX Oncology by 38.7% in the 1st quarter. UBS Group AG now owns 10,043 shares of the company’s stock valued at $45,000 after acquiring an additional 2,801 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of ALX Oncology in the 3rd quarter valued at $48,000. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

ALX Oncology Trading Up 12.4 %

ALXO opened at $14.49 on Wednesday. The stock’s fifty day moving average is $13.50 and its two-hundred day moving average is $11.84. The company has a market capitalization of $726.67 million, a P/E ratio of -3.86 and a beta of 1.58. ALX Oncology has a 52 week low of $3.94 and a 52 week high of $17.42. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.05.

ALX Oncology (NASDAQ:ALXO) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.09). Analysts forecast that ALX Oncology will post -3.33 earnings per share for the current year.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.